IL317201A - Apolipoproteins adapted with a targeting body for fat nanoparticles - Google Patents

Apolipoproteins adapted with a targeting body for fat nanoparticles

Info

Publication number
IL317201A
IL317201A IL317201A IL31720124A IL317201A IL 317201 A IL317201 A IL 317201A IL 317201 A IL317201 A IL 317201A IL 31720124 A IL31720124 A IL 31720124A IL 317201 A IL317201 A IL 317201A
Authority
IL
Israel
Prior art keywords
lipid nanoparticles
targeting body
modified apolipoproteins
apolipoproteins
modified
Prior art date
Application number
IL317201A
Other languages
English (en)
Hebrew (he)
Inventor
Der Meel Roy Van
Willem J M Mulder
Maarten Merkx
David Pepijn Schrijver
Dreu Anne De
Ayla Martine Hokke
Bruin Koen De
Original Assignee
Bio Trip B V
Der Meel Roy Van
Willem J M Mulder
Maarten Merkx
David Pepijn Schrijver
Dreu Anne De
Ayla Martine Hokke
Bruin Koen De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/076593 external-priority patent/WO2023046931A1/en
Application filed by Bio Trip B V, Der Meel Roy Van, Willem J M Mulder, Maarten Merkx, David Pepijn Schrijver, Dreu Anne De, Ayla Martine Hokke, Bruin Koen De filed Critical Bio Trip B V
Publication of IL317201A publication Critical patent/IL317201A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL317201A 2022-05-24 2023-05-24 Apolipoproteins adapted with a targeting body for fat nanoparticles IL317201A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL2031977 2022-05-24
PCT/EP2022/076593 WO2023046931A1 (en) 2021-09-23 2022-09-23 Apolipoprotein fusion proteins for cell-specific immune regulation
EP23165273 2023-03-29
PCT/EP2023/063967 WO2023227682A1 (en) 2022-05-24 2023-05-24 Modified apolipoproteins with a targeting body for lipid nanoparticles

Publications (1)

Publication Number Publication Date
IL317201A true IL317201A (en) 2025-01-01

Family

ID=86424775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317201A IL317201A (en) 2022-05-24 2023-05-24 Apolipoproteins adapted with a targeting body for fat nanoparticles

Country Status (10)

Country Link
US (1) US20260041638A1 (https=)
EP (1) EP4532026A1 (https=)
JP (1) JP2025519106A (https=)
KR (1) KR20250029793A (https=)
CN (1) CN119546627A (https=)
AU (1) AU2023277740A1 (https=)
CA (1) CA3254811A1 (https=)
IL (1) IL317201A (https=)
MX (1) MX2024014330A (https=)
WO (1) WO2023227682A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025073054A1 (en) 2023-10-05 2025-04-10 Nanovation Therapeutics Inc. Method of delivery of dna or rna cargo using unshielded lipid nanoparticles
WO2025190968A1 (en) 2024-03-11 2025-09-18 Bio-Trip B.V. Apolipoprotein lipid nanoparticle
CN119499247A (zh) * 2024-11-22 2025-02-25 中国农业大学 一种改善或治疗肠道炎症的双载药重组高密度脂蛋白纳米颗粒及其制备方法和应用
CN121059567A (zh) * 2025-11-07 2025-12-05 中国医学科学院输血研究所 一种脂质纳米颗粒及其应用、药物递送载体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013125769A1 (ko) * 2012-02-24 2013-08-29 성균관대학교 산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
KR102440820B1 (ko) * 2015-09-08 2022-09-05 테리피온, 인크. ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
CA3222851A1 (en) 2021-06-22 2022-12-29 Roy VAN DER MEEL Nucleic acid containing nanoparticles

Also Published As

Publication number Publication date
US20260041638A1 (en) 2026-02-12
CN119546627A (zh) 2025-02-28
WO2023227682A1 (en) 2023-11-30
MX2024014330A (es) 2025-01-09
AU2023277740A1 (en) 2024-11-07
EP4532026A1 (en) 2025-04-09
CA3254811A1 (en) 2023-11-30
KR20250029793A (ko) 2025-03-05
JP2025519106A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
IL317201A (en) Apolipoproteins adapted with a targeting body for fat nanoparticles
PT3908568T (pt) Lípidos para a administração de agentes ativos por nanopartículas lipídicas
WO2013148827A3 (en) Tissue thickness compensator and method for making the same
BR112013028201A2 (pt) núcleo de indutor, disposição para uma prensa e método de manufatura
CA2765694C (en) Amphoteric liposomes comprising imino lipids
PL2590626T3 (pl) Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
AU2016202489A1 (en) A luminal valve for placing in a body lumen
EP4477928A3 (en) Air delivery conduit
PL2718359T3 (pl) Sposób wytwarzania powlekanego materiału opakowaniowego i materiał opakowaniowy z co najmniej jedną warstwą barierową dla związków hydrofobowych
CL2013003755A1 (es) Aparato de fabricacion de prenda de lamina para la fabricacion de una prenda de lamina para un producto absorbente que comprende una pieza formadora de porcion lamina concava para secuencialmente formar laminas de porciones concavas de una linea de lamina de porcion concava de la primera lamina del conjunto a lo largo de una direccion de transporte, un cilindro de suministro una pieza de relleno una pieza de union de laminas.
IL299750A (en) Lipid nanoparticles for the delivery of therapeutic agents to the lungs
IL320876A (en) Compositions of stealth lipid nanoparticles for cell targeting
EP2282699A4 (en) SLEEVES FOR PLACING A STENT ON A BALLOON CATHETER INSTALLATION SYSTEM
WO2012037384A3 (en) Flexible medical tubing having kink resistant properties and methods and apparatus to produce the same
FR2962456B1 (fr) Procede de fabrication d'un cable metallique multicouches gomme in situ par un elastomere thermoplastique insature
EP2663323A1 (en) Methods targeting mir-128 for regulating cholesterol/lipid metabolism
GB201700495D0 (en) Method of manufacturing a body adhering absorbent article orientated in the machine direction wih reduced curl
WO2012027601A9 (en) Methods targeting mir-33 micrornas for regulating lipid metabolism
EP2724353B8 (en) Magnetic solenoid for generating a substantially uniform magnetic field
EP2392015A4 (en) Magnetic solenoid for generating a substantially uniform magnetic field
CA232152S (en) Lipid nanoparticle manufacturing device
GB202316478D0 (en) Lipid nanoparticles
EP4309892A4 (en) LASER-PRINTED LAMINATE DISPLAY BODY
GB202502437D0 (en) Lipid nanoparticle
CA3273031A1 (en) Lipid nanoparticle drug conjugates